Proteostasis and AveXis test the troubled IPO waters as biotech valuations wane

Damian Garde

A pair of early-stage companies has joined the thinning queue of drug developers trying to go public amid a painful market correction, angling to raise more than $ 135 million combined as the industry sputters.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS